Navigation Links
Mylan Applauds Signing of Landmark "Food and Drug Administration Safety and Innovation Act"
Date:7/9/2012

PITTSBURGH, July 9, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today applauded President Obama's signing of the "Food and Drug Administration Safety and Innovation Act," landmark legislation that will significantly enhance the safety and security of the U.S. drug supply chain, level the playing field to hold all drug manufacturers to FDA's inspection standards and improve timely access to high quality, affordable generic drugs.  

Mylan CEO Heather Bresch commented, "Mylan has long been a passionate leader and advocate for many of the key provisions included in this important piece of legislation that will help enhance our nation's drug supply chain, and we applaud the extraordinary efforts of the many in Congress who helped craft and pass this vital law in a bipartisan fashion. We believe these important updates to the 1938 law governing FDA will help to protect the health and safety of consumers by globalizing the reach of FDA to reflect today's global pharmaceutical supply chain and ensuring that all drug manufacturing facilities that supply the U.S. market are regularly inspected, regardless of whether they are based inside the U.S. or outside our borders. In particular, I am proud that the generics industry, through the landmark Generic Drug User Fee Act, has stepped up to the plate to help address an industry wide issue by providing FDA with approximately $1.5 billion over five years in order to help fund these increased inspections of drug facilities and ensure faster and more predictable review of generic drug applications."

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com


'/>"/>
SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Launches Thiamine Hydrochloride Injection
2. Mylan Launches Generic Version of Lipitor®
3. Mylan Announces Settlement Agreement in Litigation Relating to its Generic Xopenex®
4. Mylan Announces Settlement Agreement in Patent Infringement Litigation Relating to Sunovions Brovana® Product
5. Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy
6. Mylan Launches Generic Version of Viramune® Tablets
7. Mylan Sponsors Drug Store News and Pharmacist Society to Provide a New Business Networking Platform for Pharmacy Schools and Students
8. Mylan Launches Generic Version of Plavix® Tablets
9. Mylan Launches Generic Lipitor® in Five European Countries
10. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
11. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement with Teva
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2020)... ... September 01, 2020 , ... Agilent, ... the Agilent Science and Technology Virtual Symposium 2020 (ASTVS 2020) on ... open a suite of Live webinars and Networking sessions, with a vast array ...
(Date:9/1/2020)... ... September 01, 2020 , ... Neil ... serve as Secretary to the Board of Trustees and committee chair of the ... Way is a Denver-based nonprofit organization that fights for the education, health, and ...
(Date:9/1/2020)... ... September 01, 2020 , ... Breast and ovarian cancers are common diseases ... 3% of breast cancers (about 7,500 women per year) and 10% of ovarian cancers ... genes. Both genes are detectable in the Women’s Excellence Genetic Testing Program. , ...
Breaking Medicine Technology:
(Date:9/1/2020)... (PRWEB) , ... September 01, 2020 , ... Feeding ... care for children with Pediatric Feeding Disorder (PFD), is pleased to announce that the ... a stand-alone diagnostic code (R code) in the next edition of the U.S. ...
(Date:9/1/2020)... ... 2020 , ... Dr. Kiran Gill is a Board Certified ... face, breast, and body. In 2018, she founded Aesthetics in Plastic Surgery by ... practice in Southwest Florida. Dr. Gill and her team offer surgical and non-surgical ...
(Date:8/31/2020)... ... August 31, 2020 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... the 10th Anniversary of Blood Cancer Awareness Month (BCAM) and its international ...
(Date:8/31/2020)... ... August 31, 2020 , ... ... 1,400 N95 face masks to medical first responders across the United States. Since ... donations of personal protective equipment (PPE) medical centers , hospitals , ...
(Date:8/31/2020)... MARLBORO, N.J. (PRWEB) , ... August 31, 2020 ... ... the leading cloud-based business management solution for chiropractors, announced today the launch of ... telehealth, healthcare professionals can start running their virtual practice in under 90 seconds. ...
Breaking Medicine News(10 mins):